Roquefort Therapeutics (LSE:ROQ) Short-Term Capital Lease Obligation : £0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Short-Term Capital Lease Obligation?

Roquefort Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil.

Roquefort Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Roquefort Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Short-Term Capital Lease Obligation Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	-	-	-	-	-

Roquefort Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Roquefort Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines